Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.84−0.01 (-0.87%)
Close on Nov 18, 2026Market cap $65.27MP/E –Yield –
Cardiff Oncology operating margin
Operating margin is operating income as a percentage of revenue.
Cardiff Oncology's operating margin for the twelve months ending Jun 30, 2026 was -8320.1%. For fiscal 2025 it was -8256.3%, against -7123.1% the year before. The highest annual figure on record is -1076.6% in fiscal 2012.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -8256.3% | −1133.2 |
| FY2024 | Dec 31, 2024 | -7123.1% | +2182.6 |
| FY2023 | Dec 31, 2023 | -9305.7% | +1031.6 |
| FY2022 | Dec 31, 2022 | -10337.3% | −2299.7 |
| FY2021 | Dec 31, 2021 | -8037.6% | −2822.9 |
| FY2020 | Dec 31, 2020 | -5214.8% | +1603.0 |
| FY2019 | Dec 31, 2019 | -6817.8% | −2310.2 |
| FY2018 | Dec 31, 2018 | -4507.6% | +556.8 |
| FY2017 | Dec 31, 2017 | -5064.4% | +5470.5 |
| FY2016 | Dec 31, 2016 | -10534.9% | −2455.4 |
| FY2015 | Dec 31, 2015 | -8079.5% | −2745.3 |
| FY2014 | Dec 31, 2014 | -5334.2% | −1210.5 |
| FY2013 | Dec 31, 2013 | -4123.7% | −3047.1 |
| FY2012 | Dec 31, 2012 | -1076.6% | +78.5 |
| FY2011 | Dec 31, 2011 | -1155.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -9245.2% | +2967.2 |
| Q1 FY2026 | Mar 31, 2026 | -31341.5% | −18147.0 |
| Q4 FY2025 | Dec 31, 2025 | -3221.0% | +5104.8 |
| Q3 FY2025 | Sep 30, 2025 | -9978.3% | −2341.4 |
| Q2 FY2025 | Jun 30, 2025 | -12212.4% | −4516.1 |
| Q1 FY2025 | Mar 31, 2025 | -13194.5% | −7861.3 |
| Q4 FY2024 | Dec 31, 2024 | -8325.8% | −1702.8 |
| Q3 FY2024 | Sep 30, 2024 | -7637.0% | +36.8 |
| Q2 FY2024 | Jun 30, 2024 | -7696.3% | +3607.4 |
| Q1 FY2024 | Mar 31, 2024 | -5333.2% | +9187.3 |
| Q4 FY2023 | Dec 31, 2023 | -6623.1% | +714.4 |
| Q3 FY2023 | Sep 30, 2023 | -7673.8% | +1996.1 |
| Q2 FY2023 | Jun 30, 2023 | -11303.7% | +172.1 |
| Q1 FY2023 | Mar 31, 2023 | -14520.5% | +444.4 |
| Q4 FY2022 | Dec 31, 2022 | -7337.5% | −175.1 |
| Q3 FY2022 | Sep 30, 2022 | -9669.9% | −1532.7 |
| Q2 FY2022 | Jun 30, 2022 | -11475.8% | −1344.9 |
| Q1 FY2022 | Mar 31, 2022 | -14964.9% | −7406.5 |
| Q4 FY2021 | Dec 31, 2021 | -7162.4% | −1702.7 |
| Q3 FY2021 | Sep 30, 2021 | -8137.2% | −4929.1 |
| Q2 FY2021 | Jun 30, 2021 | -10130.9% | −591.3 |
| Q1 FY2021 | Mar 31, 2021 | -7558.3% | −1493.6 |
| Q4 FY2020 | Dec 31, 2020 | -5459.7% | −826.4 |
| Q3 FY2020 | Sep 30, 2020 | -3208.1% | +4932.2 |
| Q2 FY2020 | Jun 30, 2020 | -9539.5% | +1464.8 |
| Q1 FY2020 | Mar 31, 2020 | -6064.7% | +323.1 |
| Q4 FY2019 | Dec 31, 2019 | -4633.2% | +626.6 |
| Q3 FY2019 | Sep 30, 2019 | -8140.3% | −3777.2 |
| Q2 FY2019 | Jun 30, 2019 | -11004.4% | −7033.8 |
| Q1 FY2019 | Mar 31, 2019 | -6387.8% | −1739.1 |
| Q4 FY2018 | Dec 31, 2018 | -5259.9% | −3214.3 |
| Q3 FY2018 | Sep 30, 2018 | -4363.1% | +337.8 |
| Q2 FY2018 | Jun 30, 2018 | -3970.6% | +1801.6 |
| Q1 FY2018 | Mar 31, 2018 | -4648.7% | +6005.6 |
| Q4 FY2017 | Dec 31, 2017 | -2045.6% | +12340.1 |
| Q3 FY2017 | Sep 30, 2017 | -4700.9% | +6450.2 |
| Q2 FY2017 | Jun 30, 2017 | -5772.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -10654.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -14385.6% | – |
| Q3 FY2016 | Sep 30, 2016 | -11151.1% | – |
See a number that looks wrong?